Volume-2 ,Issue-7, July- 2026

The primary clinical problem is metastatic and therapy-resistant breast cancer, which continues to be the most often diagnosed cancer in women globally and a major cause of cancer-related mortality. Dose-limiting toxicities, inadequate tumor selectivity, and multidrug resistance limit conventional systemic chemotherapy and targeted therapies, prompting the hunt for safer and more efficient therapeutic approaches. Because they target the mevalonate system and have pleiotropic anti-tumor actions, such as inducing apoptosis, cell cycle arrest, and inhibiting pro-survival signaling, statins-especially the lipophilic agent simvastatin-have become intriguing drug-repurposing candidates in cancer. The pharmacokinetic and pharmacodynamic drawbacks of free simvastatin, such as poor aqueous solubility, quick first-pass metabolism, and off-target toxicity, can be addressed by lipid-based nanocarriers, such as liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid nanoemulsions. Preclinical research shows that lipidic systems loaded with simvastatin, either by themselves or in conjunction with chemotherapeutics or natural bioactives, greatly increase cytotoxicity against breast cancer cells, improve tumor growth inhibition, and decrease systemic toxicity when compared to the free drug. The translational justification for simvastatin-based nanomedicine is further supported by meta-analytic clinical data that indicate statin exposure both before and after breast cancer diagnosis is linked to decreased recurrence and enhanced overall and breast cancer-specific survival.

Keyword: Breast cancer, simvastatin, lipid nanocarrier, nanomedicine